- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01257568
Rejuvenate Modular Outcomes Study
February 15, 2022 updated by: Stryker Orthopaedics
A Prospective, Post-market, Multi-center Study of the Outcomes of the Rejuvenate® Modular Hip System
This study will be an evaluation of the Rejuvenate® Modular Hip System for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility criteria.
Subjects will be evaluated for freedom of hip revision at 5 years and clinical outcomes for up to 10 years after surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Dearborn, Michigan, United States, 48124
- Oakwood Healthcare
-
-
Minnesota
-
Sartell, Minnesota, United States, 56377
- St. Cloud Orthopaedics Associates
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
- The Orthopedic Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient has signed an IRB approved, study specific Informed Patient Consent Form.
- Patient is a male or non-pregnant female age 18 years or older at time of study device implantation.
- Patient has primary diagnosis of Non-Inflammatory Degenerative Joint Disease (NIDJD).
- Patient is a candidate for a primary cementless total hip replacement.
- Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.
- Patient's operative femur templates to Rejuvenate® Modular Stem size 7-12.
Exclusion Criteria:
- Patient has a Body Mass Index (BMI) ≥ 40.
- Patient has an active or suspected latent infection in or about the affected hip joint at time of study device implantation.
- Patient has a neuromuscular or neurosensory deficiency, which limits the ability to evaluate the safety and efficacy of the device.
- Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's Disease) leading to progressive bone deterioration.
- Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. > 30 days).
- Patient requires revision surgery of a previously implanted total hip replacement or hip fusion to the affected joint.
- Patient has a known sensitivity to device materials.
- Patient is a prisoner.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Rejuvenate Modular Hip System
Rejuvenate Modular Hip
|
Rejuvenate Modular Hip
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival Rate of the Rejuvenate Modular Stem/Neck
Time Frame: 5 years postoperative
|
The success rate is defined as freedom from Rejuvenate Modular femoral stem/neck construct revision/removal for any reason.
|
5 years postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomechanical Measurement of Femoral Offset
Time Frame: 6 weeks
|
Change from Preoperative Natural Femoral Offset to Postoperative Femoral Offset at 6-weeks postoperative measured in millimeters.
|
6 weeks
|
Biomechanical Measurement of the Vertical Distance of the Planned Hip Center of Rotation
Time Frame: 6 weeks
|
Change from preoperative vertical distance of the anatomic hip center to the planned center of rotation of the hip to the postoperative distance from the planned center of rotation at 6 weeks measured in millimeters.
|
6 weeks
|
Biomechanical Measurement of the Horizontal Distance of the Planned Hip Center of Rotation
Time Frame: 6 weeks
|
Change from preoperative horizontal distance of the anatomic hip center to the planned center of rotation of the hip to the postoperative distance from the planned center of rotation at 6 weeks measured in millimeters.
|
6 weeks
|
Mean Harris Hip Score at Each Visit
Time Frame: pre-op, 6 wk, 1, 2, 3, 4, 5, 7 year
|
The Harris Hip Score (HHS) assesses pain, function, joint deformity and range of motion. Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score of less than or equal to 79 is considered fair-poor. 90-100 = excellent 80-89 = good 70-79 = fair 0-69 = poor |
pre-op, 6 wk, 1, 2, 3, 4, 5, 7 year
|
Mean SF-12 Scores at Each Visit
Time Frame: pre-op, 6 wk, 1, 2, 3, 4, 5, 7 year
|
The SF-12 Health Survey is a 12-item patient completed questionnaire to measure general health and well-being.
It includes a physical and mental status component score; each ranging from 0-100.
Low values represent a poor health state and high values represent a good health state.
|
pre-op, 6 wk, 1, 2, 3, 4, 5, 7 year
|
Mean Lower Extremity Activity Scale (LEAS) Scores at Each Visit
Time Frame: pre-op, 6 wk, 1, 2, 3, 4, 5, 7 year
|
The LEAS is completed by the participant to assess activity level.
Activity levels were ordered in terms of intensity from 1 to 18, with 18 indicating the highest activity level.
|
pre-op, 6 wk, 1, 2, 3, 4, 5, 7 year
|
Occurrence of Subsidence at Six Weeks, Stem Migration, Unstable Fixation and Radiographic Instability (Radiolucency)
Time Frame: 6 wks,1,2,3,4,5 yrs
|
Radiographic stability of the stem is defined as having the following: no radiographic indication of progressive radiolucent lines greater than or equal to 2 mm around the entire femoral component, and no radiographic indication of progressive subsidence of the femoral component of great than or equal to 5 mm.
Only subsidence was measured at 6 weeks, migration and fixation are analyzed beginning at 1 year postoperative.
|
6 wks,1,2,3,4,5 yrs
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yogesh Mittal, M.D., The Orthopedic Center
- Principal Investigator: Joseph Nessler, M.D., St. Cloud Orthopaedic Associates
- Principal Investigator: Lawrence Morawa, M.D., Oakwood Healthcare System
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (ACTUAL)
June 6, 2017
Study Completion (ACTUAL)
January 20, 2022
Study Registration Dates
First Submitted
December 8, 2010
First Submitted That Met QC Criteria
December 8, 2010
First Posted (ESTIMATE)
December 9, 2010
Study Record Updates
Last Update Posted (ACTUAL)
February 16, 2022
Last Update Submitted That Met QC Criteria
February 15, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- 68
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthroplasty, Replacement, Hip
-
Fondazione Don Carlo Gnocchi OnlusCompletedArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipItaly
-
Bornholms RegionskommuneCompletedArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipDenmark
-
Campus Bio-Medico UniversityRecruitingArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipItaly
-
SCRI Development Innovations, LLCWithdrawnArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipUnited States
-
Sunnybrook Health Sciences CentreActive, not recruitingArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipCanada
-
University of British ColumbiaThe Arthritis Society, Canada; Centre for Aging SMART; Centre for Advancing Health...Not yet recruitingArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipCanada
-
University Hospital, Strasbourg, FranceRecruitingArthroplasty, Hip Replacement | Arthroplasty, Knee ReplacementFrance
-
Henry Ford Health SystemConsumer Sleep SolutionsNot yet recruitingArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipUnited States
-
Haute Ecole de Santé VaudCompletedArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipSwitzerland
-
The Cleveland ClinicZimmer Biomet; Accelero Health Partners, LLCCompletedArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipUnited States
Clinical Trials on Rejuvenate Modular Hip
-
Encore Medical, L.P.DJO IncorporatedTerminatedTraumatic Fracture | Osteolysis | Aseptic Loosening | Failed Total Hip ImplantUnited States
-
Smith & Nephew, Inc.TerminatedTotal Hip Arthroplasty (THA)Australia
-
Stryker OrthopaedicsCompletedArthroplasty, Replacement, HipUnited States
-
Spokane Joint Replacement CenterCompletedOsteoarthritis, HipUnited States
-
Region SkaneCompletedOsteoarthritisSweden
-
MicroPort Orthopedics Inc.Active, not recruitingJoint DiseaseCanada
-
Korea University Guro HospitalStryker Korea Co., Ltd.Active, not recruitingArthroplasty Complications | Femur Neck FractureKorea, Republic of
-
Ottawa Hospital Research InstituteJohnson & JohnsonCompletedTotal Hip ArthroplastyCanada
-
MicroPort Orthopedics Inc.Terminated
-
Sykehuset Asker og BaerumUllevaal University HospitalCompleted